Exscientia secures £49m Series C investment led by Novo Holdings to scale operations
Novo Holdings led the financing round to support portfolio expansion and international growth.
Exscientia is a clinical stage pharmatech company that uses artificial intelligence to design patient based drugs. The company operates an automated platform to advance precision medicines from target identification to clinical trials.
Exscientia has raised £49m in a Series C financing round led by Novo Holdings, with continued participation from existing backers Evotec, Bristol Myers Squibb, and GT Healthcare Capital. The newly secured capital will support the expansion of the company pipeline, the progression of advanced projects into clinical trials, and the scaling of its American operations.
The firm has made significant progress in deploying automated systems to reduce timelines from target identification to candidate selection. Recent milestones include advancing an artificial intelligence designed molecule into human clinical trials within twelve months, alongside forming broad partnerships across the pharmaceutical sector.
From the founder
"This investment highlights the increasing commitment to the potential of AI to transform drug discovery and the excitement that we have garnered around the innovative work we are doing at Exscientia"
Andrew Hopkins
CEO at Exscientia
Investor perspective
"Through its impressive track record to date, Exscientia has demonstrated the value of combining deep scientific expertise with cutting-edge technology capabilities to significantly accelerate drug discovery. Novo Holdings’ investment underscores our interest in supporting technology companies that enable life science research and innovation, and our commitment to this area. We see significant opportunity for the company to further grow its participation in the drug discovery ecosystem and are excited to work with the Exscientia team in realising this vision."
Robert Ghenchev
Managing Partner of Growth Investments, Novo Holdings
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Categories
About the company
Exscientia
Exscientia builds artificial intelligence platforms to design and discover new medicines.